Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy


Gibson C. M., Korjian S., Chi G., Daaboul Y., Jain P., Arbetter D., ...Daha Fazla

JOURNAL OF THE AMERICAN HEART ASSOCIATION, cilt.6, sa.7, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 7
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1161/jaha.117.006015
  • Dergi Adı: JOURNAL OF THE AMERICAN HEART ASSOCIATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: death, intracranial hemorrhage, ischemic stroke, myocardial infarction, pulmonary embolism, venous thromboembolism, THROMBOPROPHYLAXIS
  • Gazi Üniversitesi Adresli: Evet

Özet

Background-Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically III VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.